We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Phase 1 Trial of PAN-301-1 (SNS-301) in Cancer Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03120832
Recruitment Status : Completed
First Posted : April 19, 2017
Results First Posted : November 12, 2021
Last Update Posted : November 12, 2021
Information provided by (Responsible Party):
Sensei Biotherapeutics, Inc.

Brief Summary:
This is a Phase I, open-label, parallel design study of PAN-301-1 (SNS-301), a HAAH directed nanoparticle vaccine, given intradermally in cohorts of patients with biochemically relapsed prostate cancer, using a fixed dose escalation schema every 21 days.

Condition or disease Intervention/treatment Phase
Prostate Cancer Biological: PAN-301-1 Phase 1

Detailed Description:

Human aspartyl-asparaginyl-β-hydroxylase (HAAH), also known as aspartate-β-hydroxylase, is an ~86 kDa type 2 transmembrane protein that belongs to the α-ketoglutarate-dependent dioxygenase family. It is a highly conserved enzyme, which catalyzes the hydroxylation of aspartyl and asparaginyl residues in epidermal growth factor-like domains of proteins including Notch and homologs. HAAH was initially identified in a novel screen to identify cell surface proteins up-regulated in liver cancer. It has subsequently been detected in a diverse array of solid and blood cancers, including: liver, bile duct, brain, breast, colon, prostate, ovary, pancreas, and lung cancers as well as leukemia. HAAH is not found in significant quantities in normal tissue or in proliferative disorders.

The investigators have designed a bacteriophage lambda system to display HAAH peptides fused at the C terminus of the head protein gpD of phage lambda. The phage carry 200-300 copies of the gpD protein on their head and thus display many copies of an approximately 25 kDa molecular weight fragment of HAAH on their surface. The drug substance is one of these HAAH bacteriophage lambda constructs: HAAH-1λ (PAN-301-1).

This study evaluates the safety and immunogenicity of the PAN-301-1 vaccine in patients with biochemically-relapsed prostate cancer.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: N/A
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1, Open Label Trial to Evaluate the Safety and Immunogenicity of PAN-301-1 in Cancer Patients
Study Start Date : December 2016
Actual Primary Completion Date : December 2018
Actual Study Completion Date : December 2018

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: PAN-301-1 (SNS-301) Vaccine
PAN-301-1 vaccine is administered intradermally in 3 cohorts of patients in a dose escalation schema every 21 days
Biological: PAN-301-1
Other Name: SNS-301

Primary Outcome Measures :
  1. Safety Assessed by Development of Adverse Events and Dose-limiting Toxicity to Determine Maximum Tolerated Dose [ Time Frame: Through the 21 day interval after the first dose of vaccine ]

Secondary Outcome Measures :
  1. Safety Assessed by Administration Site Reactions, Abnormal Laboratory Values and/or Adverse Events [ Time Frame: Through study completion, an average of 3 months. Patients were able to continue on treatment with one patient receiving approximately 15 months of treatment. ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   21 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Must be male subject having diagnosis of prostate cancer
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Signed and dated written Ethics Committee approved informed consent
  2. Men aged 21 to 85 years with a histologic diagnosis of prostate cancer with a biochemical relapse following definitive local therapy (RP or radiation therapy)
  3. Patients are not eligible or are unwilling to receive additional definitive therapy following relapse (either RP or radiation therapy)
  4. No prior cytotoxic chemotherapy for the current cancer
  5. Normal electrocardiogram (ECG) or ECG with no clinically significant findings as determined by the Principal Investigator
  6. Presence of biochemically relapsed prostate cancer defined as either: 1) PSA > 2 ng/mL 1 year following initial definitive treatment for prostate cancer: or, 2) PSA doubling time (greater than 0.2 ng/mL) < 12 months; or, 3) PSA velocity > 2 ng/mL/year at any time following radical prostatectomy or radiation therapy.
  7. Positive expression of HAAH in either archived tumor tissue (if available) or fresh serum
  8. No clinical or radiologic evidence of distant metastatic disease as measured by pelvic MRI or CT scan in addition to bone scan. These studies will need to be performed within 56 (+ 7 days) days prior to the start of the study.
  9. No history of immunosuppressive disease
  10. No evidence of active autoimmune disease. Active autoimmune disease is defined as any disease process that has specifically needed administration of immune suppressive and or cytoreductive therapy currently or within the last 1 year.
  11. Able and willing to comply with all study procedures

Exclusion criteria:

  1. PSA doubling time of < 3 months
  2. Participation in a clinical trial within 30 days prior to enrollment
  3. Prior major surgery or radiation therapy within 4 weeks of enrollment
  4. Any illness or condition that in the opinion of the Investigator may affect the safety of the patient or the evaluation of any study endpoint
  5. Screening blood counts of the following:


    Absolute neutrophil count < 1500/μL, Platelets < 100,000/μL, Hemoglobin < 9 g/dL;


    Alanine aminotransferase (ALT) and aspartate transaminase (AST) > 2.5 × ULN range, Total bilirubin > 2 × ULN, Albumin < 2.8 g/dL;


    Creatinine clearance < 50 mL/min as predicted by the Cockcroft-Gault formula

  6. Subjects whose partners are WOCBP must use an adequate method of birth control while on study drug and at least for 3 weeks after discontinuation of study drug
  7. Current or anticipated concomitant immunosuppressive therapy (excluding nonsystemic inhaled, topical skin and/or eye drop-containing corticosteroids)
  8. Any concurrent condition requiring the continued use of systemic steroids (see above) or the use of immunosuppressive agents including methotrexate. All other systemic corticosteroids must be discontinued at least 4 weeks prior to first study treatment
  9. Receipt of any blood product within 1 month of enrollment
  10. Receipt of any vaccine within 4 weeks of enrollment
  11. Active drug or alcohol use or dependence that, in the opinion of the Investigator, would interfere with adherence to study requirements
  12. Been imprisoned or compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (i.e. infectious disease) illness
  13. Patients who have a history of coagulopathies, thrombosis or who are receiving active anticoagulation for any condition, such as but not limited to, artificial heart valves, atrial fibrillation, etc.
  14. Any other conditions judged by the Investigator that would limit the evaluation of a subject

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03120832

Layout table for location information
United States, Alabama
Urology Centers of Alabama
Homewood, Alabama, United States, 35209
United States, California
Dr. James J. Elist
Beverly Hills, California, United States, 90211
United States, Nebraska
GU Research Network/Urology Cancer Center
Omaha, Nebraska, United States, 68130
United States, South Carolina
Carolina Urologic Research Center
Myrtle Beach, South Carolina, United States, 29572
Sponsors and Collaborators
Sensei Biotherapeutics, Inc.
  Study Documents (Full-Text)

Documents provided by Sensei Biotherapeutics, Inc.:
Study Protocol  [PDF] June 12, 2018
Statistical Analysis Plan  [PDF] December 21, 2018

Layout table for additonal information
Responsible Party: Sensei Biotherapeutics, Inc.
ClinicalTrials.gov Identifier: NCT03120832    
Other Study ID Numbers: PAN0216
First Posted: April 19, 2017    Key Record Dates
Results First Posted: November 12, 2021
Last Update Posted: November 12, 2021
Last Verified: October 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
Neoplasms by Site
Prostatic Diseases